comparemela.com

Latest Breaking News On - Nathalie meetz - Page 1 : comparemela.com

Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A

United-states
Japan
Switzerland
America
Nathalie-meetz
Levi-garraway
Loren-kalm
Chugai-pharmaceutical-co-ltd
Genentech
International-society-on-thrombosis
European-commission
Drug-administration

Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2

Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
United-states
Switzerland
Nathalie-meetz
Birgit-masjost
Thomas-schinecker
Sabine-borngr
Gerard-tobin
Bruno-eschli
Genentech
World-health-organization
European-union

Roche's Elecsys Amyloid Plasma Panel granted FDA

The Elecsys Amyloid Plasma Panel is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for.

Japan
United-states
Switzerland
America
Nathalie-meetz
Sileia-urech
Loren-kalm
Thomas-schinecker
Karsten-kleine
World-alzheimer-report-reveals-disease-international
Genentech
World-health-organization

F. Hoffmann-La Roche Ltd: Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.The Elecsys HCV Duo

Switzerland
Geneva
Genè
Japan
United-states
America
Nathalie-meetz
Birgit-masjost
Loren-kalm
Thomas-schinecker
Sabine-borngr
Gerard-tobin

F. Hoffmann-La Roche Ltd: New two-year data confirm Roche's Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration

In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo received

Japan
Ireland
United-states
United-kingdom
Switzerland
America
Irish
American
Nathalie-meetz
Levi-garraway
Birgit-masjost
Loren-kalm

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.